SARS-CoV-2 infection drives local inflammation of the intestinal epithelium in immunocompromised patients with cancer.

Cancer patients undergoing transplantation-based treatments can develop graft-versus-host disease (GVHD), an inflammatory condition that increases mortality risk. In this study, we analyzed three cancer patients with severe inflammatory disorders following SARS-CoV-2 infection using high-resolution microscopy and spatial transcriptomics on pre- and post-infection gastrointestinal (GI) biopsies. We found that up to 49 days after infection, the duodenal epithelium retained COVID viral elements, showed increased expression of viral receptors, inflammatory genes, and interferon activity, and exhibited tissue scarring. Notably, SERPINA1 was a persistent marker of infection and inflammation, also present in ∼600 GI tumor samples, suggesting its role as a broader inflammation marker. These findings indicate that the GI epithelium can serve as a long-term COVID reservoir, potentially driving inflammatory syndromes similar to GVHD. This persistent viral presence may pose additional risks for cancer patients undergoing transplantation, highlighting the need for further investigation into post-COVID inflammatory complications in cancer patients.